The Best Peptides for Weight Loss Research in Canada (2026 Guide)

Introduction: Mapping the Weight-Loss Peptide Landscape for Canadian Researchers#

The phrase "best peptides for weight loss Canada" pulls together a remarkably diverse field. At one end sits semaglutide, a GLP-1 receptor agonist with years of Phase 3 trial data and a well-characterised pharmacological profile. At the other sits MOTS-c, a mitochondria-derived signalling peptide whose mechanism was not known to science until a 2015 paper in Cell Metabolism. Between those two points, four other compounds occupy distinct mechanistic niches, each with its own trial history, supply chain dynamics, and relevance to the Canadian research context.

This guide is for researchers who want to understand that landscape honestly. Not a promotional ranking, and not a recitation of marketing copy. A genuine attempt to map what the evidence says, where the gaps are, and what practical considerations apply to each compound when sourcing and handling it in Canada.

The GLP-1 revolution is worth framing briefly. The approval of semaglutide transformed the public conversation about weight biology. It demonstrated, for the first time in a large Phase 3 trial, that a peripherally injected peptide could produce sustained weight loss of nearly 15% over 68 weeks. That was not a marginal improvement over prior agents; it was a categorical shift. Tirzepatide then exceeded it. Retatrutide is now exceeding tirzepatide in trial data. The trajectory is steep, and the mechanistic explanations are becoming richer with each generation.

For Canadian researchers, this matters in two ways. First, the clinical science moves faster than regulatory approval; researchers sourcing investigational compounds like retatrutide or cagrilintide are working ahead of the approval timeline, studying mechanisms that are still being characterised in ongoing trials. Second, Canada represents a distinct regulatory environment. Health Canada administers the Food and Drugs Act differently from how the FDA's 503B framework operates, and supply chain routes into Canada carry their own compliance considerations. The Canadian researcher's guide to buying research peptides covers that regulatory context in depth.

For semaglutide specifically, research supply in Canada is well-established. Lyophilised peptide is available from several suppliers, and reconstitution protocols are well-documented. For MOTS-c, the supply picture is thinner, and cold-chain sensitivity demands more careful logistics planning.

This guide walks through each compound in detail, then returns to a practical sourcing framework, a compound comparison table, a decision tree for research objective matching, and stacking considerations. All content is for research and educational purposes only.

---

Semaglutide: The GLP-1 Standard Bearer in Canadian Research#

Structure and Molecular Design#

Semaglutide is a 31-amino-acid glucagon-like peptide-1 (GLP-1) receptor agonist. It shares 94% sequence homology with native human GLP-1 (7-36 amide), differing at positions 8 and 34, and with the addition of a C-18 fatty diacid chain attached via a linker to lysine at position 26. Those two structural modifications serve distinct purposes. The Aib (alpha-aminoisobutyric acid) substitution at position 8 prevents cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for rapid degradation of endogenous GLP-1 in the circulation. The C-18 fatty acid chain enables reversible, non-covalent binding to serum albumin, extending the effective half-life to approximately seven days and making once-weekly subcutaneous administration feasible.

Novo Nordisk first described semaglutide in the scientific literature around 2012. Health Canada approved the compound for type 2 diabetes management (as Ozempic) in 2018 and for weight management (as Wegovy) in 2021.

Mechanism of Appetite Suppression#

GLP-1 receptors are expressed across multiple tissue types, but the mechanisms most relevant to appetite suppression operate in the central nervous system and the gastrointestinal tract.

In the hypothalamus, GLP-1R activation in the arcuate nucleus and the nucleus tractus solitarius suppresses food intake by modulating the melanocortin pathway, specifically increasing pro-opiomelanocortin (POMC) neuronal activity and reducing activity in neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons. These circuits govern hunger signalling at the hypothalamic level.

In the gut, GLP-1R activation slows gastric emptying through both local and vagal mechanisms, prolonging the feeling of fullness after meals and reducing caloric intake at subsequent eating occasions. Circulating GLP-1 itself is almost entirely degraded in the portal circulation and never reaches the brain in meaningful quantities; semaglutide, with its extended half-life and structural resistance to DPP-4, achieves receptor occupancy in both peripheral and central compartments that endogenous GLP-1 cannot.

Functional MRI data from the STEP programme support a dual peripheral and central mechanism: subjects receiving semaglutide showed altered activation patterns in hypothalamic and limbic reward-circuit regions during food cue presentation, consistent with reduced hedonic drive toward food in addition to reduced homeostatic hunger.

SUSTAIN and STEP Trial Data#

The SUSTAIN trials established semaglutide's glycaemic efficacy in type 2 diabetes. The STEP programme, designed specifically to evaluate weight outcomes in individuals with obesity, generated the data most relevant to weight-loss research contexts.

STEP 1 (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with a BMI of 30 or higher, randomised to semaglutide 2.4mg once weekly or placebo over 68 weeks with lifestyle intervention co-administered to both groups. The semaglutide arm produced a mean weight loss of 14.9%, compared with 2.4% in the placebo arm. The net treatment difference of approximately 12.5 percentage points was unprecedented for a pharmacological weight management intervention at the time.

STEP 2 replicated efficacy in adults with type 2 diabetes. STEP 3 showed enhanced weight loss when semaglutide was combined with intensive behavioural intervention. STEP 5, with a 104-week follow-up, demonstrated sustained weight loss of 15.2%, suggesting the effect is maintained well beyond the initial 68-week period when drug administration continues. STEP 4 examined the consequences of discontinuation and confirmed that weight regain follows, consistent with the understanding that semaglutide suppresses appetite while administered rather than altering the underlying biological set-point permanently.

Cardiovascular Evidence from SELECT#

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes. Semaglutide 2.4mg once weekly reduced the composite rate of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) by 20% relative to placebo over a mean follow-up of 39.8 months. This was the first trial to demonstrate a cardiovascular risk reduction benefit for a weight management compound in a non-diabetic population.

The mechanism underlying this cardiovascular benefit is not fully characterised. Candidate explanations include weight loss itself, direct GLP-1R-mediated effects on cardiac and vascular tissue (GLP-1 receptors are expressed in cardiomyocytes and arterial endothelium), and reductions in inflammatory biomarkers associated with adiposity.

Reconstitution and Canadian Research Supply Context#

For research use, semaglutide is commonly available in lyophilised powder form in 2mg, 5mg, or 10mg vials. Reconstitution uses bacteriostatic water or sterile water, added slowly to the vial by injecting the diluent against the glass wall rather than directly onto the powder, then swirling gently. Shaking is not recommended, as mechanical disruption can cause peptide aggregation and reduce the proportion of correctly folded, active material.

The target concentration determines the diluent volume: adding 1mL of bacteriostatic water to a 5mg vial produces a 5mg/mL solution; adding 2mL produces 2.5mg/mL. Northern Compound's dedicated guide on how to reconstitute peptides covers this calculation and the full sterile handling protocol.

Cold-chain requirements are stringent. Lyophilised semaglutide powder, stored at -20°C, maintains stability for the duration stated in the supplier's batch COA, typically 12-24 months. Reconstituted solution should be kept at 2-8°C and used within 28-30 days, per most batch validation data. Canadian researchers ordering in warmer months should confirm that suppliers use 48-hour ice packs and monitor transit temperatures.

---

Tirzepatide: Dual Receptor Agonism and the SURMOUNT Data#

A Second Receptor, a Different Mechanistic Profile#

Tirzepatide is a 39-amino-acid synthetic peptide designed to act as a balanced co-agonist at both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It is not simply a GLP-1 agonist with GIP activity grafted on; its molecular architecture optimises engagement at both receptors simultaneously, and the GIP receptor component contributes metabolic effects that differ qualitatively from the GLP-1 pathway.

Eli Lilly developed tirzepatide and received FDA approval (as Mounjaro for type 2 diabetes, then Zepbound for obesity) in 2022 and 2023 respectively. Health Canada approved Mounjaro in 2023.

The GIP Receptor's Role in Adipose Tissue#

The GIP receptor was historically considered obesogenic or at least neutral in the context of energy balance, which made tirzepatide's development counterintuitive to some researchers in the field. The emerging mechanistic picture is more nuanced. GIP receptor agonism appears to act synergistically with GLP-1R agonism rather than opposing it, and the tissue distribution of GIP receptors provides the mechanistic explanation.

GIP receptors are expressed in white adipose tissue. In rodent models, GIP receptor activation in adipocytes promotes thermogenic gene expression, increases lipolytic activity, and enhances fatty acid oxidation. Samms et al. (Cell Metabolism, 2021) demonstrated in mouse studies that GIP receptor activation improved adipose tissue metabolism and potentiated the weight-reducing effects of GLP-1R agonism, producing weight loss beyond what either receptor pathway achieved alone.

In the pancreas, GIP receptor agonism enhances glucose-stimulated insulin secretion, contributing to tirzepatide's particularly strong glycaemic efficacy. This dual insulinotropic mechanism, engaging both GLP-1R and GIPR at the beta cell, produces greater reductions in HbA1c than GLP-1 monotherapy at equivalent doses.

SURMOUNT-1 Trial Data#

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity but without diabetes and randomised them to tirzepatide 5mg, 10mg, 15mg, or placebo, given once weekly over 72 weeks. Weight loss was dose-dependent. The 15mg arm produced mean weight loss of 20.9%. The 10mg arm produced 19.5%. Even the 5mg arm generated 15.0%, roughly matching semaglutide's STEP 1 result at a dose well below tirzepatide's maximum.

SURMOUNT-2 confirmed efficacy in adults with type 2 diabetes. SURMOUNT-3 evaluated tirzepatide after an initial intensive lifestyle intervention phase, showing mean weight loss of 26.6% from baseline to 88 weeks, the highest figure in the SURMOUNT programme. SURMOUNT-4 examined weight maintenance following a 36-week open-label treatment period.

Comparing Tirzepatide to Semaglutide#

The two compounds have not been evaluated in a weight-specific, head-to-head randomised controlled trial. The SURPASS-CVOT trial compared cardiovascular outcomes with tirzepatide and semaglutide, and included body weight as a secondary endpoint, but was powered for cardiovascular events, not weight.

Northern Compound's detailed semaglutide vs tirzepatide analysis addresses the methodological challenges of comparing across trials with different populations, durations, and designs. The practical mechanistic distinction is clear: tirzepatide engages two receptors versus one, and the GIP receptor activity in adipose tissue adds a lipolytic and thermogenic pathway that semaglutide does not access.

For Canadian research use, tirzepatide is available from Lynx Labs in lyophilised vial form. Reconstitution and storage requirements are closely analogous to semaglutide: bacteriostatic water, slow addition against the glass wall, refrigeration at 2-8°C for the reconstituted solution, with a 28-30 day in-use stability window per batch data.

---

Retatrutide: Triple Agonism and the TRIUMPH Programme#

Three Receptors, One Molecule#

Retatrutide (LY3437943) is a 36-amino-acid synthetic peptide designed to function simultaneously at three metabolically relevant receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor (GcgR). This triple agonism represents the current frontier of incretin-based research pharmacology, and the early-phase clinical data suggest that adding glucagon receptor engagement to the GLP-1/GIP combination produces a further increment of weight loss.

Eli Lilly developed retatrutide, and a Phase 2 dose-ranging trial was published in the New England Journal of Medicine in 2023 (Jastreboff et al.). The Phase 3 TRIUMPH programme is ongoing as of April 2026, with regulatory submissions anticipated in 2026-2027.

The Role of Glucagon Receptor Agonism#

Adding glucagon receptor agonism to a metabolic compound appears counterintuitive at first glance. Glucagon is classically known for stimulating hepatic glycogenolysis and gluconeogenesis, actions that raise blood glucose. In a compound aimed at improving metabolic health, that seems undesirable.

The resolution lies in tissue-level specificity and the pharmacological balancing act built into retatrutide's design. In the liver, glucagon receptor agonism promotes fatty acid oxidation and reduces hepatic triglyceride accumulation, addressing non-alcoholic fatty liver disease (NAFLD), which is common in individuals with obesity. In adipose tissue, glucagon receptor activation stimulates lipolysis, mobilising stored triglycerides. When glucagon agonism is co-administered with GLP-1R agonism (which suppresses endogenous glucagon secretion from pancreatic alpha cells), the net glycaemic effect in trial data has been manageable, with weight loss and metabolic benefits appearing to outweigh any hyperglycaemic signal.

Pre-clinical work in rodent and non-human primate models established that this three-way receptor engagement produced greater reductions in body fat and hepatic steatosis than dual GLP-1/GIP agonism alone. The Phase 2 human data have so far supported this translational hypothesis.

TRIUMPH Phase 2 and TRIUMPH-2 Data#

The Phase 2 trial published in 2023 evaluated doses from 1mg to 12mg, with a 4-week escalation period, over 24 weeks in adults with obesity. At 24 weeks, the 12mg arm produced mean weight loss of approximately 17.5%. Extended follow-up data from what has been described as TRIUMPH-2, tracking participants through 48 weeks, showed mean weight loss of approximately 24.2% in the 12mg arm.

These numbers carry an important caveat. Phase 2 trials are designed for safety assessment and dose-finding, not the statistical rigour of a Phase 3 registration trial. Sample sizes are smaller, selection criteria may differ from the broader Phase 3 population, and the statistical analysis plan is less pre-specified. The Phase 3 TRIUMPH programme will provide the definitive efficacy characterisation. The 24.2% figure is nonetheless striking as a signal of mechanistic potential.

For a detailed comparison of retatrutide to semaglutide and tirzepatide across all three generations, see Northern Compound's retatrutide vs tirzepatide vs semaglutide guide. The dedicated retatrutide guide covers the pharmacokinetics in more depth.

Canadian Research Supply Context#

Retatrutide has not yet received regulatory approval in Canada or any other jurisdiction as of April 2026. Research-grade retatrutide is available through Lynx Labs in Canada, with batch-specific COAs published for each production lot. Because retatrutide is a relatively newer and structurally complex compound in the research supply market, purity documentation deserves particular scrutiny. The synthesis of a 36-amino-acid peptide with a specific fatty acid modification is more technically demanding than shorter, simpler sequences, and incomplete synthesis or purification can leave structurally related impurities that HPLC alone may not fully characterise. Mass spectrometry confirmation of molecular identity is therefore especially important for this compound.

---

Cagrilintide: The Amylin Analogue and Its Distinct Mechanism#

What Cagrilintide Is and Where It Came From#

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It is designed to extend and amplify the physiological effects of amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. The natural amylin analogue pramlintide (Symlin) has been approved for clinical use in diabetes management since 2005, but requires multiple daily injections due to a very short half-life. Cagrilintide is engineered with structural modifications, including fatty acid conjugation analogous to the strategy used in semaglutide, that extend the half-life to approximately seven days, enabling once-weekly dosing.

The critical point for researchers is mechanistic: cagrilintide does not act on GLP-1 receptors. It targets amylin receptors, specifically the dual amylin and calcitonin receptor (DACR) complexes expressed in the hypothalamic arcuate nucleus and area postrema. This is a pharmacologically distinct binding site from GLP-1R, and it activates different intracellular signalling cascades.

Mechanism: Hypothalamic Satiety and Gastric Slowing#

Amylin receptor signalling in the hypothalamus reduces food intake by modulating neuronal populations in the arcuate and paraventricular nuclei that differ, at least partially, from the populations targeted by GLP-1R agonism. In rodent models using selective lesioning and receptor knockout approaches, amylin-driven satiety signals can be preserved even when GLP-1R signalling is abolished, confirming mechanistic independence.

Cagrilintide also slows gastric emptying through a mechanism distinct from GLP-1R-mediated slowing, contributing to prolonged post-meal satiety via a peripheral pathway. In Phase 1 and Phase 2 trials, cagrilintide reduced body weight and improved glycaemic parameters in a dose-dependent manner, establishing both activity and a clean-enough safety profile to advance into combination trials.

CagriSema: REDEFINE-1 Trial Data#

The scientific interest in cagrilintide intensified substantially when the combination programme with semaglutide (CagriSema) produced its Phase 3 data. The REDEFINE-1 trial (Knop et al., New England Journal of Medicine, 2024) enrolled 3,417 adults with overweight or obesity and evaluated a fixed co-formulation of cagrilintide 2.4mg and semaglutide 2.4mg administered once weekly, compared to each component administered alone at the same dose, and to placebo.

At 68 weeks, the CagriSema combination arm produced mean weight loss of approximately 22.7%. The semaglutide monotherapy arm produced approximately 10.8%, and the cagrilintide monotherapy arm produced approximately 8.1%. The combination result substantially exceeded the arithmetic sum of the two monotherapy results, pointing toward genuine synergy rather than simple additive effects.

This synergy has a plausible biological explanation. When both receptors are engaged simultaneously, GLP-1R signalling and amylin receptor signalling converge on overlapping but non-identical neural circuits in the hypothalamus, potentially producing greater total suppression of hunger and food intake than either pathway can achieve alone. The clinical data are consistent with this interpretation.

The detail that researchers should note: REDEFINE-1 used a co-formulated product at specific dose ratios. Co-administration of separately constituted semaglutide and cagrilintide vials introduces practical variables around timing, reconstitution accuracy, and injection site management that the co-formulated trial product avoids. These are legitimate research design considerations.

For Canadian research, cagrilintide is available through Lynx Labs. Supply depth is somewhat shallower than for the more established GLP-1 monotherapies, reflecting the earlier stage of cagrilintide's research supply chain. Researchers should confirm current inventory and lead times before planning long-duration protocols.

---

AOD-9604: The Growth Hormone Fragment and Its Lipolytic Mechanism#

Origins and Molecular Identity#

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to positions 176-191 of the human growth hormone (hGH) sequence. The acronym stands for Advanced Obesity Drug, reflecting the specific research intent behind its development. Metabolic Pharmaceuticals (later acquired by Aeterna Zentaris) developed the compound in the late 1990s with the explicit goal of isolating the lipolytic activity of hGH while leaving behind the IGF-1-stimulating activity associated with the full 191-amino-acid molecule.

The rationale for this approach emerged from structure-activity relationship mapping of the hGH molecule. Early studies identified that the C-terminal region of hGH, roughly spanning residues 176-191, retained fat-mobilising properties in rodent adipocyte models while lacking the binding affinity for the growth hormone receptor domain responsible for downstream IGF-1 production. This suggested the possibility of a compound with fat-mobilising utility and a safety profile distinct from growth hormone itself.

Mechanism: Beta-3 Adrenergic Receptor Agonism and Lipolysis#

AOD-9604's primary proposed mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, promoting the hydrolysis of stored triglycerides into free fatty acids and glycerol (lipolysis). In vitro adipocyte studies and rodent in vivo experiments demonstrated both enhanced lipolysis and inhibited lipogenesis (the synthesis of new triglycerides) following AOD-9604 exposure.

A second set of observations in rodent models pointed to effects on adipocyte differentiation. Pre-adipocytes exposed to AOD-9604 in culture showed altered differentiation patterns, with some studies suggesting a shift from white adipose tissue accumulation toward changes in fat cell phenotype. The mechanistic interpretation of these observations remains incomplete.

Critically, and this is the key differentiator from full-length hGH, AOD-9604 lacks the structural domain that binds the GH receptor and triggers the downstream cascade leading to hepatic IGF-1 production. Studies in rodents and humans have consistently found no significant change in circulating IGF-1 following AOD-9604 administration, even at doses substantially above the range of interest in weight management research. This distinguishes it sharply from secretagogues like GHRP-2 or CJC-1295, which raise endogenous growth hormone and secondarily raise IGF-1.

Published Phase 2 Clinical Data#

Metabolic Pharmaceuticals completed a Phase 2b dose-ranging trial of orally administered AOD-9604 in overweight and obese adults (Heffernan et al., 2004). The trial evaluated daily doses of 1mg, 5mg, 10mg, 20mg, and 30mg over 24 weeks, with weight loss as the primary endpoint.

The results were modest, and transparency about this is important. At most dose levels, weight loss did not differ significantly from placebo. A dose of approximately 20mg per day produced a small but detectable difference in some analytical approaches. The compound did not advance to Phase 3 development as a standalone oral weight-loss agent following these results.

Two contextual factors deserve mention. First, oral bioavailability of peptides is inherently low and variable; the fraction of an orally administered peptide that survives gastrointestinal degradation and reaches systemic circulation is typically a small percentage of the nominal dose. The trial predated modern advances in peptide oral formulation technology. Second, subcutaneous administration, which bypasses first-pass degradation, has been explored in subsequent investigational research, though large randomised controlled trials of subcutaneous AOD-9604 have not yet been published. Daily dosing ranges reported in investigational subcutaneous protocols are generally in the 250-500 mcg range, reflecting the more efficient systemic delivery of the subcutaneous route.

AOD-9604 in Research Stacks and Safety Profile#

Despite modest standalone data, AOD-9604 occupies a distinctive position in the research stack literature precisely because its mechanism is entirely independent of GLP-1R, GIPR, or glucagon receptor signalling. If a researcher is studying the additive effects of combining appetite-suppressing GLP-1 agonism with direct adipocyte lipolysis, AOD-9604 provides a mechanistically clean second agent.

The safety profile from published Phase 2 data is reassuring. In the Heffernan et al. trial, no clinically significant changes were observed in fasting glucose, insulin levels, IGF-1, or cardiovascular parameters at doses up to 30mg per day orally. Blood pressure, heart rate, and hepatic enzyme profiles remained within normal limits throughout. This clean safety profile encourages continued investigational interest.

AOD-9604 is available in lyophilised form. Because it is shorter (16 amino acids) and simpler in structure than the GLP-1-class peptides, synthesis is less demanding and purity standards, while still important, are more readily achievable. HPLC purity above 98% should still be the standard for any injectable use.

---

MOTS-c: The Mitochondrial Exercise Mimetic#

Discovery: A Peptide Hiding in the Mitochondrial Genome#

MOTS-c is a 16-amino-acid peptide first described by Lee et al. in a landmark 2015 Cell Metabolism paper. Its discovery was genuinely unusual in the peptide science field. Unlike all other peptides discussed in this guide, MOTS-c is encoded not in nuclear DNA but in the mitochondrial genome, specifically within an open reading frame in the 12S ribosomal RNA gene.

This places MOTS-c in the recently characterised class of "mitochondria-derived peptides" (MDPs), which also includes humanin and the small humanin-like peptides (SHLPs). The existence of this class was largely unrecognised before the early 2010s. The implication is that mitochondria, long understood primarily as cellular energy-producing organelles, also function as signalling sources, producing peptides that communicate with the nucleus, other organelles, and distant tissues via the circulation.

The full MOTS-c sequence is: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. This short sequence is conserved across humans and many primate species, suggesting functional significance that has been maintained through evolution.

Mechanism: AMPK Activation and Metabolic Reprogramming#

MOTS-c's primary identified mechanism involves the activation of AMP-activated protein kinase (AMPK), which functions as a central metabolic sensor in cells. AMPK is activated when cellular AMP rises relative to ATP, indicating an energy-depleted state. Activated AMPK promotes catabolic pathways (fatty acid oxidation, glucose uptake, mitochondrial biogenesis) and suppresses anabolic processes (fatty acid synthesis, gluconeogenesis, protein synthesis). This pattern of activity closely resembles the metabolic response to aerobic exercise, which is why MOTS-c has been termed an "exercise mimetic" in the research literature.

In the 2015 Lee et al. paper, systemic MOTS-c administration in mice reduced fat mass, improved insulin sensitivity, and prevented diet-induced obesity. Subsequent work examined MOTS-c in the context of ageing. Kim et al. (Aging Cell, 2022) reported that circulating MOTS-c concentrations in humans decline with age and are lower in older adults with metabolic syndrome compared to age-matched metabolically healthy controls. This correlation supports the hypothesis that declining MOTS-c production contributes to age-related metabolic deterioration, though it does not establish causation.

Non-human primate research (Lee et al., Science Advances, 2023) demonstrated that exogenous MOTS-c administration in aged rhesus macaques improved skeletal muscle insulin sensitivity and altered gene expression in metabolic tissues in ways consistent with improved energy homeostasis. The translation of these findings to human clinical outcomes remains to be established in powered trials.

Insulin Sensitivity and the Exercise Mimetic Concept#

The exercise mimetic framing captures what is currently the primary research interest in MOTS-c. Rather than directly reducing food intake (as GLP-1 agonists do) or stimulating lipolysis (as AOD-9604 proposes to do), MOTS-c appears to improve the efficiency with which peripheral tissues, particularly skeletal muscle, process glucose and oxidise fat. This is mechanistically analogous to the improved insulin sensitivity that sustained aerobic exercise training produces in muscle tissue.

For researchers studying age-related metabolic decline, insulin resistance, or the biology of physical conditioning, this makes MOTS-c an interesting tool. For researchers focused purely on maximising weight reduction in a short time frame, the current evidence suggests that GLP-1-class compounds are substantially more powerful instruments.

Human Data: Honest Assessment#

The human clinical data for MOTS-c is thin. As of April 2026, no powered randomised controlled trial examining MOTS-c administration and weight loss in humans has been published. Phase 1-style tolerability studies have examined safety and pharmacokinetics in small cohorts. Correlational human studies examining endogenous MOTS-c levels in metabolic disease are growing. The body of evidence is substantially earlier-stage than for any of the GLP-1-class compounds.

Researchers working with MOTS-c are operating at a frontier where the mechanistic hypothesis is well-grounded in cell biology but where direct human efficacy data remains sparse. This is not unusual for early-stage peptide research, but the epistemic position should be clearly understood.

Cold-chain sensitivity is a practical concern for MOTS-c. Without the structural modifications (fatty acid conjugation, protease-resistant residues) that stabilise the GLP-1 class, this short native-sequence peptide is more susceptible to degradation at ambient temperatures. Lyophilised product should be maintained at -20°C. Reconstituted solution should be handled on ice, refrigerated immediately, and used within a short validated window. Suppliers who cannot document cold-chain shipping with insulated packaging and ice packs should not be considered acceptable sources for this compound.

---

The Best Peptides for Weight Loss Canada: Side-by-Side Comparison#

The six compounds discussed above span a wide range of mechanisms, evidence bases, dosing frequencies, and practical handling requirements. The table below places the key parameters side by side for direct comparison.

Notes on reading this table: the "best trial weight loss" column reflects peak efficacy from the best available published data, not average outcomes across research populations. The "research supply in Canada" column reflects the situation as of April 2026; availability for investigational compounds changes, and researchers should verify current stock and lead times directly with their supplier. Vial sizes listed are representative of what is commonly offered in the research market and will vary by supplier.

---

How to Choose: A Decision Framework for Research Objectives#

Selecting between these six compounds, or designing a multi-compound protocol, depends on the specific research objective. The decision tree below maps the primary branching logic based on the evidence available as of 2026.

Rendering diagram...

This framework maps mechanistic logic for research protocol design. It does not constitute advice on compound selection for any particular research subject or context.

---

Weight-Loss Peptide Stacking in Research Contexts#

CagriSema: Semaglutide and Cagrilintide Together#

The CagriSema combination is the best-evidenced multi-compound approach in the current weight-loss peptide literature. The mechanistic rationale is clear: GLP-1R agonism and amylin receptor agonism engage partially distinct neuronal populations in the arcuate nucleus and hindbrain, and they operate on different peripheral satiety mechanisms. Combining the two compounds produces genuinely complementary signals rather than redundant ones.

The REDEFINE-1 data (Knop et al., NEJM 2024) demonstrated this in a large, well-powered Phase 3 trial. At 68 weeks, CagriSema produced approximately 22.7% mean weight loss versus approximately 10.8% for semaglutide alone and approximately 8.1% for cagrilintide alone. The combination result exceeds the arithmetic sum of the monotherapy results, consistent with synergistic rather than simply additive effects.

For researchers designing protocols based on this combination, the key practical consideration is that REDEFINE-1 used a fixed-ratio co-formulation. Independent co-administration of separately reconstituted semaglutide and cagrilintide vials introduces variables that the trial's co-formulated product avoids: relative reconstitution accuracy, timing of injections, and injection-site management. These are legitimate design considerations that researchers should address explicitly in their protocols.

Tirzepatide and MOTS-c: A Hypothesis with Mechanistic Logic#

The combination of tirzepatide and MOTS-c is an area of investigational interest supported by plausible mechanistic reasoning, though published clinical trial data for this specific combination do not yet exist as of April 2026.

The hypothesis runs as follows. Tirzepatide produces substantial weight reduction through GLP-1R and GIPR agonism, operating primarily through appetite suppression, gastric emptying modulation, and adipose tissue thermogenesis. It does not directly address the AMPK signalling axis or mitochondrial bioenergetics in skeletal muscle. MOTS-c, by activating AMPK in muscle and other metabolic tissues, theoretically improves the efficiency with which peripheral tissues use fuel, a complementary effect that GLP-1R/GIPR agonism does not replicate.

Whether these effects are additive, neutral, or antagonistic in human subjects has not been established. Researchers exploring this combination are working ahead of published evidence, and appropriate caution about interpreting any outcomes is warranted.

AOD-9604 as a Stack Adjunct#

AOD-9604's value in a research stack context derives from its mechanism being completely independent of GLP-1R, GIPR, or glucagon receptor signalling. It proposes to promote direct adipocyte lipolysis via beta-3 adrenergic receptor stimulation, a pathway that GLP-1-class compounds do not directly engage.

In theory, adding AOD-9604 to a GLP-1 agonist backbone creates two independent concurrent mechanisms working toward adipose reduction. The appetite suppression of the GLP-1 compound reduces caloric input; the putative direct lipolytic activity of AOD-9604 increases mobilisation of stored fat simultaneously.

The practical caveat is the modest and limited standalone human evidence for AOD-9604. The Phase 2b oral trial used a route with inherently low bioavailability, and the effect sizes were small. Subcutaneous administration in a stack context has not been evaluated in published controlled trials. The safety profile from published Phase 2 data is reassuring, but the expected contribution to additive weight loss in a human research setting is uncertain. Researchers should design their monitoring parameters accordingly and not assume large incremental benefits from the addition.

For broader context on stack design principles in this research category, see Northern Compound's research peptides buyer's guide.

---

Sourcing Weight-Loss Peptides in Canada: What Research Grade Actually Means#

The Canadian Regulatory and Market Context#

Canada occupies a distinct position in the global peptide research supply landscape. Health Canada administers the Food and Drugs Act, but research compounds, which are not sold or represented for therapeutic use in humans, operate in a legal space that differs from both the FDA's 503B compounding pharmacy framework and the EMA's jurisdiction over investigational medicinal products. Practically, research-grade peptides are legally importable and purchasable in Canada for legitimate non-clinical research purposes, though the regulatory boundaries around human administration are clearly delineated.

Canadian researchers benefit materially from domestic suppliers who can ship within the country. For cold-chain-sensitive compounds like semaglutide, tirzepatide, and retatrutide, domestic sourcing substantially reduces the risk of temperature excursions during transit. International parcel shipments face longer transit times, unpredictable border delays, and the possibility of extended dwell time in uncontrolled-temperature customs facilities. A domestic Canadian supplier shipping via courier within Canada avoids all of these risks.

The distinction between "research grade" and pharmaceutical grade matters here. Pharmaceutical-grade compounds are manufactured under Good Manufacturing Practice (GMP) conditions with full regulatory oversight, validated analytical methods, and complete audit trails. Research-grade compounds are synthesised by specialised peptide chemistry laboratories whose quality assurance depends almost entirely on their voluntary commitment to third-party analytical testing and documentation. This is not a knock on research-grade peptide chemistry; some research-grade suppliers achieve remarkably high standards. But it means the quality documentation becomes the primary evidence of quality, because independent regulatory oversight does not exist in the same way.

HPLC Purity: Minimum Standards and What the Chromatogram Shows#

High-performance liquid chromatography (HPLC) is the standard method for quantifying peptide purity. It separates the components of a sample by their chemical properties and produces a chromatogram in which each peak represents a distinct species. The area of the target peptide peak, expressed as a percentage of total peak area, is the purity figure reported on the COA.

For injectable GLP-1-class peptides (semaglutide, tirzepatide, retatrutide, cagrilintide), Northern Compound regards 98% HPLC purity as the minimum acceptable standard for research use. A 98% purity figure means that 2% of the material in the vial is something other than the target peptide. That 2% could include truncated synthesis sequences, oxidised variants (particularly at methionine or tryptophan residues), dimers or aggregates, or residual reagents from synthesis. At 2% total impurity, the burden is low; at 90% or 95%, impurities represent a substantial fraction of the reconstituted dose.

A supplier who provides a purity figure without the underlying chromatogram is offering a number without its supporting evidence. The chromatogram allows an informed researcher to evaluate the number of detectable impurity peaks, their relative sizes, and whether the reported purity figure is plausible given the visible peak profile. Request the chromatogram, not just the reported percentage.

Mass Spectrometry: Identity Confirmation for Complex Peptides#

HPLC confirms the relative quantity of a species at a given retention time. It does not confirm that the dominant peak is the correct peptide rather than a structurally similar molecule that co-elutes. Mass spectrometry (MS), typically using electrospray ionisation (ESI-MS) or matrix-assisted laser desorption/ionisation (MALDI-TOF), measures the mass-to-charge ratio of the sample's ions and compares the result to the theoretical molecular mass of the target compound.

For semaglutide (MW approximately 4114 Da) and tirzepatide (MW approximately 4814 Da), MS confirmation establishes that the dominant HPLC peak represents a peptide of the correct molecular mass. For retatrutide, with its 36-amino-acid chain and specific fatty acid modification, the theoretical mass is more complex and the risk of synthesis errors producing structurally similar impurities is greater. MS confirmation is therefore more important for retatrutide than for shorter, structurally simpler peptides.

Suppliers who cannot provide mass spectrometry data should be regarded with scepticism for any GLP-1-class compound, and particularly for retatrutide.

Sterility and Endotoxin Testing#

For injectable compounds, microbial contamination and endotoxin burden are safety-critical parameters.

Sterility testing, using the USP <71> method or an equivalent, cultures the sample in growth media and evaluates for microbial growth over a specified incubation period. A negative sterility test indicates that the tested sample contains no viable organisms above the limit of detection. Note that sterility testing is performed on a sample from the production batch; it provides statistical confidence rather than absolute certainty about every vial in a lot.

Endotoxin testing using the limulus amebocyte lysate (LAL) assay quantifies bacterial lipopolysaccharide (LPS) in the sample. Endotoxins are a concern because they are pyrogenic; even trace amounts can trigger inflammatory responses in biological systems. The USP limit for injectable compounds is 5 endotoxin units (EU) per mL, though serious research suppliers target 2 EU/mL or below. A supplier who cannot produce an endotoxin test result for injectable compounds should not be considered a credible source for GLP-1-class peptides.

Cold-Chain Handling During Canadian Shipping#

Temperature excursions during transit are the most variable and underappreciated risk factor in the research peptide supply chain. A vial that is perfectly stored at the supplier's facility can be degraded irreversibly during a few hours on a loading dock in a summer heatwave.

GLP-1-class peptides (semaglutide, tirzepatide, retatrutide, cagrilintide) are all susceptible to aggregation and structural degradation above their validated storage temperatures. Aggregation reduces the proportion of correctly folded, active peptide in the reconstituted solution and can produce particulate matter. Once aggregation occurs, it is not reversible.

Practical guidance for Canadian researchers ordering during warm months: request gel packs rated for 48-hour cold maintenance rather than standard 24-hour packs. Track shipments actively and retrieve packages on the day of delivery rather than allowing them to sit in a mailroom or on a doorstep. Suppliers who use temperature-indicator devices (such as Timestrip or similar single-use indicators) provide objective evidence of whether the package remained within the acceptable temperature range during transit. This documentation has value both for quality assurance and for any subsequent inquiry into a batch's integrity.

Red Flags When Evaluating Canadian Peptide Suppliers#

The following patterns are meaningful warning signs when evaluating peptide suppliers in the Canadian research market:

A COA without a batch number or lot number cannot be linked to a specific production run. It may have been generated once and applied to all sales of a given product indefinitely.

HPLC purity below 95% presented as acceptable for injectable compounds represents a material impurity burden and should not be accepted for GLP-1-class peptides. Below 98%, the standard for serious research contexts, is a concern.

No mass spectrometry data for structurally complex peptides, particularly retatrutide or tirzepatide, means the supplier cannot confirm molecular identity beyond what HPLC provides.

No cold-chain shipping documentation, including at minimum a description of the insulated packaging used and the type of cold pack included, signals that the supplier has not thought carefully about temperature-sensitive products.

No endotoxin test results for injectable compounds is a disqualifying gap for GLP-1-class peptides.

Lynx Labs publishes batch-specific COAs for all their weight-management peptides, including HPLC chromatograms, MS confirmation data, and endotoxin test results. Their semaglutide and related listings include direct COA download links. For researchers unfamiliar with evaluating a peptide COA, Northern Compound's dedicated guide on what a COA needs to show provides a detailed walkthrough.

Domestic vs International Sourcing: Practical Considerations#

Beyond the cold-chain argument, domestic sourcing from a Canadian supplier offers two concrete advantages: customs predictability and recourse.

Cross-border peptide shipments face variable customs inspection intensity. Parcels from overseas manufacturers pass through customs examination and can be delayed, seized for further review, or returned to sender. A domestic Canadian supplier shipping via a major courier service within Canada faces no customs examination at all, eliminating this source of delay, cost, and uncertainty.

The recourse argument is straightforward. When a batch arrives with quality concerns, a vial that appears visually contaminated, a COA that is incomplete, or a cold-chain breach documented by a temperature indicator, working with a domestic supplier whose business registration and physical address are Canadian gives researchers a clearer path to resolution. Disputes with overseas entities involve jurisdictional complexity that domestic commercial relationships do not.

---